Q001: A NEW FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS

At Quodria, we have partnered with world experts at the University of Liverpool, UK and Galytx  (www.galytx.com) to produce Q001, a light cream formulation with emollient properties that targets Galectin-3. Galectin-3 is a multi-modal protein that is disregulated in AD and produces both pro-inflammatory and pro-fibrotic effects in the skin and local immune cells. Q001 will be a first-in-class topical treatment for AD supporting skin barrier function whilst treating localized inflammation and allowing the skin to recover. 

The aim is for Q001 to be complementary to both current and future AD treatments that can be used by all AD patients to treat flares and successfully manage their disease.